Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1995 Jan;50(1):54–61. doi: 10.1136/thx.50.1.54

Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients.

B J Lipworth 1, D M Newnham 1, R A Clark 1, D P Dhillon 1, J H Winter 1, D G McDevitt 1
PMCID: PMC473709  PMID: 7886650

Abstract

BACKGROUND--There is controversy as to the relative safety of fenoterol and salbutamol. No differences have been found in the relative cardiac beta 1/beta 2 receptor activity of inhaled fenoterol and salbutamol in normal subjects. These initial findings have been extended by comparing the respective potencies of equivalent doses by weight of fenoterol and salbutamol in asthmatic subjects, in terms of airways and systemic responses. METHODS--Eighteen asthmatic patients of mean (SD) age 40 (14) years and a forced expiratory volume in one second (FEV1)% predicted of 56 (14)% (1.97 (0.66)1) were randomised to inhale fenoterol (100 micrograms/puff or 200 micrograms/puff), salbutamol, or placebo (100 micrograms/puff or 200 micrograms/puff) on three separate days. Dose-response curves were constructed using cumulative doses of 100 micrograms, 200 micrograms, 400 micrograms, 1000 micrograms, 2000 micrograms, and 4000 micrograms, and airways and systemic responses were measured 20 minutes after each dose with 40 minute increments. Dose ratios for the relative potency of fenoterol versus salbutamol were calculated from the dose-response curves using regression analysis of parallel slopes. RESULTS--There was no difference in bronchodilator potency between fenoterol and salbutamol (as median dose ratio): FEV1 1.1 (95% CI 0.4 to 4.6). In contrast, dose ratios for systemic responses showed that fenoterol was more potent than salbutamol: serum potassium 3.7 (95% CI 2.0 to 6.0), tremor 5.7 (95% CI 1.4 to 10.2), heart rate 1.6 (95% CI 1.0 to 2.3). At a conventional dose of 200 micrograms the only difference in response between the two drugs was observed for tremor (as mean difference): 0.23 log units (95% CI 0.06 to 0.41 log units). CONCLUSIONS--There was no difference in the bronchodilator potency between fenoterol and salbutamol on a microgram equivalent basis. In contrast, systemic potency was greater with fenoterol, although this difference was not clinically relevant at conventional dosages up to 200 micrograms.

Full text

PDF
54

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bremner P., Burgess C., Beasley R., Woodman K., Marshall S., Crane J., Pearce N. Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Respir Med. 1992 Sep;86(5):419–423. doi: 10.1016/s0954-6111(06)80009-0. [DOI] [PubMed] [Google Scholar]
  2. Brodde O. E., Brinkmann M., Schemuth R., O'Hara N., Daul A. Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen. J Clin Invest. 1985 Sep;76(3):1096–1101. doi: 10.1172/JCI112063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Collins J. M., McDevitt D. G., Shanks R. G., Swanton J. G. The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol. 1969 May;36(1):35–45. doi: 10.1111/j.1476-5381.1969.tb08301.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Crane J., Pearce N., Flatt A., Burgess C., Jackson R., Kwong T., Ball M., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet. 1989 Apr 29;1(8644):917–922. doi: 10.1016/s0140-6736(89)92505-1. [DOI] [PubMed] [Google Scholar]
  5. Goldie R. G., Spina D., Henry P. J., Lulich K. M., Paterson J. W. In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline. Br J Clin Pharmacol. 1986 Dec;22(6):669–676. doi: 10.1111/j.1365-2125.1986.tb02956.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Grainger J., Woodman K., Pearce N., Crane J., Burgess C., Keane A., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax. 1991 Feb;46(2):105–111. doi: 10.1136/thx.46.2.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lipworth B. J., Clark R. A., Dhillon D. P., McDevitt D. G. Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol. Eur J Clin Pharmacol. 1990;38(2):203–205. doi: 10.1007/BF00265986. [DOI] [PubMed] [Google Scholar]
  8. Lipworth B. J., McDevitt D. G. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol. 1989;36(3):239–245. doi: 10.1007/BF00558154. [DOI] [PubMed] [Google Scholar]
  9. Lipworth B. J., McDevitt D. G., Struthers A. D. Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. Am J Med. 1989 Jun;86(6 Pt 1):653–657. doi: 10.1016/0002-9343(89)90438-5. [DOI] [PubMed] [Google Scholar]
  10. Lipworth B. J. Risks versus benefits of inhaled beta 2-agonists in the management of asthma. Drug Saf. 1992 Jan-Feb;7(1):54–70. doi: 10.2165/00002018-199207010-00007. [DOI] [PubMed] [Google Scholar]
  11. Lipworth B. J., Struthers A. D., McDevitt D. G. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis. 1989 Sep;140(3):586–592. doi: 10.1164/ajrccm/140.3.586. [DOI] [PubMed] [Google Scholar]
  12. Mügge A., Posselt D., Reimer U., Schmitz W., Scholz H. Effects of the beta 2-adrenoceptor agonists fenoterol and salbutamol on force of contraction in isolated human ventricular myocardium. Klin Wochenschr. 1985 Jan 2;63(1):26–31. [PubMed] [Google Scholar]
  13. Newhouse M. T., Dolovich M. B., Kazim F. Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma. Chest. 1994 Jun;105(6):1738–1742. doi: 10.1378/chest.105.6.1738. [DOI] [PubMed] [Google Scholar]
  14. Newnham D. M., Wheeldon N. M., Lipworth B. J., McDevitt D. G. Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax. 1993 Jun;48(6):656–658. doi: 10.1136/thx.48.6.656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. O'Donnell S. R., Wanstall J. C. Evidence that the efficacy (intrinsic activity) of fenoterol is higher than that of salbutamol on beta-adrenoceptors in guinea-pig trachea. Eur J Pharmacol. 1978 Feb 1;47(3):333–340. doi: 10.1016/0014-2999(78)90241-8. [DOI] [PubMed] [Google Scholar]
  16. Pearce N., Grainger J., Atkinson M., Crane J., Burgess C., Culling C., Windom H., Beasley R. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax. 1990 Mar;45(3):170–175. doi: 10.1136/thx.45.3.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Robson S. C., Murray A., Peart I., Heads A., Hunter S. Reproducibility of cardiac output measurement by cross sectional and Doppler echocardiography. Br Heart J. 1988 Jun;59(6):680–684. doi: 10.1136/hrt.59.6.680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rominger K. L., Mentrup A., Stiasni M. Radioimmunological determination of fenoterol. Part II: Antiserum and tracer for the determination of fenoterol. Arzneimittelforschung. 1990 Aug;40(8):887–895. [PubMed] [Google Scholar]
  19. Scheinin M., Koulu M., Laurikainen E., Allonen H. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol. 1987 Nov;24(5):645–653. doi: 10.1111/j.1365-2125.1987.tb03224.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Spitzer W. O., Suissa S., Ernst P., Horwitz R. I., Habbick B., Cockcroft D., Boivin J. F., McNutt M., Buist A. S., Rebuck A. S. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992 Feb 20;326(8):501–506. doi: 10.1056/NEJM199202203260801. [DOI] [PubMed] [Google Scholar]
  21. Stewart D. E., Ikram H., Espiner E. A., Nicholls M. G. Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease. Br Heart J. 1985 Sep;54(3):290–297. doi: 10.1136/hrt.54.3.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. White P. C., New M. I., Dupont B. Cloning and expression of cDNA encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci U S A. 1984 Apr;81(7):1986–1990. doi: 10.1073/pnas.81.7.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wilson C., Lincoln C. Beta-adrenoceptor subtypes in human, rat, guinea pig, and rabbit atria. J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1216–1221. [PubMed] [Google Scholar]
  24. Windom H. H., Burgess C. D., Siebers R. W., Purdie G., Pearce N., Crane J., Beasley R. The pulmonary and extrapulmonary effects of inhaled beta-agonists in patients with asthma. Clin Pharmacol Ther. 1990 Sep;48(3):296–301. doi: 10.1038/clpt.1990.152. [DOI] [PubMed] [Google Scholar]
  25. Wong C. S., Pavord I. D., Williams J., Britton J. R., Tattersfield A. E. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet. 1990 Dec 8;336(8728):1396–1399. doi: 10.1016/0140-6736(90)93099-b. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES